The most common side effects of Ozempic are digestive issues, particularly nausea, vomiting, diarrhea, constipation, and stomach pain. These affect a significant portion of users, especially during the first weeks of treatment and after dose increases. Most of these symptoms improve as your body adjusts, but some people experience them throughout treatment.
Why Ozempic Causes Digestive Problems
Ozempic (semaglutide) works by mimicking a hormone called GLP-1, which your body naturally releases after eating. This hormone acts on three key areas: the pancreas, where it triggers insulin release; the brain’s appetite center, where it signals fullness; and the stomach’s nerve cells, where it slows down how quickly food moves through your digestive system.
That slowed stomach emptying is central to how the drug works. It keeps you feeling full longer and reduces appetite, which is why people lose weight on it. But it’s also the reason so many users feel nauseated, bloated, or uncomfortably full after meals that would have seemed normal before. Your stomach is simply holding onto food longer than it used to.
Common Side Effects and How Long They Last
Nausea is by far the most frequently reported issue. Vomiting, diarrhea, constipation, and abdominal pain follow closely behind. These tend to be worst during the first few weeks on a new dose. Ozempic is prescribed on a titration schedule, starting at 0.25 mg per week for the first four weeks before your doctor considers increasing the dose. Each step up can temporarily bring back or worsen symptoms.
For many people, digestive side effects fade as the body adjusts to each dose level. Some users, however, continue to experience nausea or other stomach issues at higher doses. If symptoms remain severe, your doctor may keep you at a lower dose longer before increasing or may decide a lower maintenance dose is appropriate.
Reducing Nausea and Stomach Discomfort
Dietary adjustments make a real difference. The core strategy is working with your slower digestion rather than against it:
- Eat smaller meals more frequently instead of three large ones. Your stomach empties more slowly now, so large volumes of food sit longer and trigger more nausea.
- Avoid greasy and fried foods. High-fat meals are already slow to digest, and Ozempic amplifies that effect.
- Eat slowly and stop when you feel satisfied, not when your plate is clean. You will feel full faster than you’re used to.
- Stay upright for at least 30 minutes after eating. Lying down slows digestion further and can worsen nausea.
- Limit alcohol, which can compound both nausea and digestive slowdown.
Muscle Loss During Weight Loss
When you lose weight on Ozempic, you don’t lose only fat. Research shows that semaglutide-induced weight loss includes a reduction in lean mass (muscle and other non-fat tissue) alongside fat loss. This isn’t unique to the drug. Any significant weight loss, whether from medication, surgery, or dieting, typically involves some muscle loss.
There’s a nuance worth noting: while total lean mass drops, the ratio of lean mass to overall body weight tends to improve, meaning you’re losing proportionally more fat than muscle. Still, larger trials have found meaningful reductions in lean mass. Strength training and adequate protein intake during treatment can help preserve muscle, which matters particularly for older adults who are already at risk for age-related muscle loss.
Eye Complications in People With Diabetes
People with type 2 diabetes who already have diabetic retinopathy (damage to blood vessels in the eye) face a specific risk. Ozempic can cause a large, rapid drop in blood sugar levels, particularly during the first 16 weeks. That fast improvement in blood sugar control has been linked to worsening retinopathy.
This phenomenon isn’t new to Ozempic. It has been observed since the 1990s in people starting insulin who achieved rapid glucose control. One theory is that a sudden drop in blood sugar triggers changes in the tiny blood vessels of the retina, increasing leakiness and potentially worsening existing damage. The concern appears to be about the speed of the blood sugar change rather than the medication itself. If you have diabetic retinopathy, your doctor will likely want to monitor your eyes more closely after starting treatment.
Severe Digestive Reactions
Beyond ordinary nausea and discomfort, the FDA label carries warnings about more serious gastrointestinal problems. Ozempic is not recommended for people with severe gastroparesis, a condition where the stomach already empties abnormally slowly. Adding a drug that further delays stomach emptying can make the condition significantly worse.
Ileus, a condition where the intestines temporarily stop moving food through, has been reported in post-marketing surveillance. This is rare but serious, potentially requiring hospitalization. Symptoms include severe bloating, cramping, inability to pass gas, and vomiting. These are distinct from the typical mild-to-moderate digestive side effects most users experience.
Pancreatitis Risk
Inflammation of the pancreas (pancreatitis) has been a concern with this class of drugs for years. The evidence, however, is more reassuring than alarming. A meta-analysis pooling data across semaglutide trials found no increased risk of acute pancreatitis compared to placebo. The odds were actually slightly lower in the semaglutide groups, though not enough to claim a protective effect.
That said, pancreatitis remains listed as a warning on the label, and cases have been reported. Symptoms to watch for include severe, persistent abdominal pain that radiates to the back, often accompanied by vomiting. If you experience this kind of pain, it warrants prompt medical evaluation, as pancreatitis can become dangerous quickly.
The Thyroid Cancer Warning
Ozempic carries the FDA’s most serious warning category, a boxed warning, about the risk of thyroid C-cell tumors. In two-year studies, rodents given semaglutide developed thyroid tumors at doses comparable to or above what humans receive. Both mice and rats showed statistically significant increases in these tumors, with rats developing them at every dose tested.
Whether this applies to humans remains unknown. The FDA label states plainly that “human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.” Rodent thyroid cells respond differently to GLP-1 than human thyroid cells do, which is why researchers can’t simply extrapolate the animal findings. However, out of caution, Ozempic is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a genetic condition called Multiple Endocrine Neoplasia syndrome type 2. Symptoms that would warrant attention include a lump in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness.